997 results on '"Chabannon, C."'
Search Results
202. Autologous stem cell transplantation for acute myelogenous leukemia in first complete remission: a 6-year follow-up study of 101 patients from a single institution
203. S3 - PBSC collection technologies and graft composition
204. Les relations recherche publique / industrie génomique : américanisation ou voie européenne ?
205. Essential requirements for setting up a stem cell processing laboratory.
206. Efficacy and safety of micafungin for prophylaxis of invasive fungal infections in patients undergoing haplo-identical hematopoietic SCT.
207. Outpatient sequential alkylating regimen with stem cell support for patients with breast cancer
208. Production of ex vivo expanded hematopoietic cells and progenitors in a closed bioreactor, starting with a small volume marrow collection: A feasibility study in patients with poor-risk breast cancer and receiving high-doses of cyclophosphamide.
209. The role of autologous hematopoietic progenitor and cell reinfusion for intensive chemotherapy in women with poor-prognosis breast cancer. Clinical studies with ex-vivo expanded cells produced with the Aastrom Replicell® technology
210. Ex vivo manipulations alter the reconstitution potential of mobilized human CD34+ peripheral blood progenitors
211. Positive selection of CD34+ peripheral blood progenitor cells in patients with low-grade lymphoid malignancies and bone marrow involment
212. CD34+ cell enumeration in peripheral blood and apheresis samples, using two laboratory diagnostic kits or an institutional protocol
213. Mobilisation of healthy donors with lenograstim and transplantation of HLA-genoidentical blood progenitors in 54 patients with hematological malignancies: a pilot study
214. High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer: a randomized multicentre study
215. O3-3 Production ex vivo et réinjection de progéniteurs hématopoïétiques autologues: une étude clinique pilote chez six patientes atteintes d'un cancer du sein
216. P3-13 Étude comparative de la numération des cellules hématopoïétiques CD34+ aux moyens de deux trousses diagnostiques et d'une méthode interne à l'Institut Paoli-Calmettes
217. Le transfert incertain de la science vers la médecine : l'exemple des systèmes de sélection de cellules CD34+.
218. Faible expression d'un transgène dans des cellules souches hématopoïétiques reconstituant des lignées myéloïde, lymphoïde B et lymphoïde T de la souris SCID humanisée.
219. OP18. Optimization of peripheral blood stem cell collection (PBSC) by leukapheresis: a case of interaction between economic and clinical assessment of an innovation
220. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma.
221. Autologous Transplantation of Blood Stern Cells Mobilized with Filgrastim Alone in 93 Patients with Malignancies: The Number of CD34+ Cells Reinfused Is the Only Factor Predicting Both Granulocyte and Platelet Recovery
222. Phenotypic, molecular, and functional characterization of human peripheral blood CD34+/THY1+ cells
223. Transfert de gènes dans les cellules hématopoïétiques : obscur objet du désir de voir et de manipuler la vraie cellule souche ?
224. Granulocyte colony-stimulating factor-mobilized allogeneic peripheral blood stem cells for rescue graft failure after allogeneic bone marrow transplantation in two patients with acute myeloblastic leukemia in first complete remission [letter]
225. Les cellules souches hématopoïétiques du sang périphérique chez l'homme
226. Disease status is a more reliable predictive factor than histology in lymphoma patients after reduced-intensity conditioning regimen and allo-SCT.
227. Implementation of JACIE accreditation results in the establishment of new indicators that unevenly monitor processes contributing to the delivery of hematopoietic SCT.
228. Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigen-matched, related allogeneic peripheral blood stem cell transplantation: Prospective clinical and socioeconomic evaluation.
229. Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin's lymphoma.
230. Expression of CD7 on normal human myeloid progenitors.
231. The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT.
232. Randomized study of early hospital discharge following autologous blood SCT: medical outcomes and hospital costs.
233. Ancestim (r-metHuSCF) plus filgrastim and/or chemotherapy for mobilization of blood progenitors in 513 poorly mobilizing cancer patients: the French compassionate experience.
234. Development of an enhanced B-specific lentiviral vector expressing BTK: a tool for gene therapy of XLA.
235. Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma.
236. CD34+ progenitors are reproducibly recovered in thawed umbilical grafts, and positively influence haematopoietic reconstitution after transplantation.
237. A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma.
238. Greffe de cellules souches hématopoïétiques après conditionnement atténué dans les leucémies aiguës myéloblastiques.
239. Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy.
240. Early administration of recombinant erythropoietin improves hemoglobin recovery after reduced intensity conditioned allogeneic stem cell transplantation.
241. rhG-CSF does not affect the phenotype of adult donor peripheral blood NK cells.
242. Les banques de tissus tumoraux appliquées au cancer du sein : pourquoi ? Comment ?
243. Autologous stem cell transplantation for acute myelogenous leukemia in first complete remission: a 6-year follow-up study of 101 patients from a single institution.
244. Occult tumor cell contamination in patients with stage II/III breast cancer receiving sequential high-dose chemotherapy.
245. Functional characterization of human CD34+ cells that express low or high levels of the membrane antigen CD111 (nectin 1).
246. Preclinical evaluation of an automated closed fluid management device: CytomateTM, for washing out DMSO from hematopoietic stem cell grafts after thawing.
247. Ovarian cancer/ Intensive sequential dose dense chemotherapy with stem cell support at first-line treatment in advanced ovarian carcinoma: a phase II study.
248. Analysis of donor NK and T cells infused in patients undergoing MHC-matched allogenic hematopoietic transplantation.
249. Modulations of dose intensity of doxorubicin and cyclophosphamide in association with G-CSF and peripheral blood stem cells in adjuvant chemotherapy for breast cancer: comparative evaluation of completion and safety of three intensive regimens.
250. Aiolos and Ikaros: Regulators of lymphocyte development, homeostasis and lymphoproliferation.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.